Observations Lobby Watch

The Stockholm Network

BMJ 2010; 341 doi: http://dx.doi.org/10.1136/bmj.c6413 (Published 10 November 2010) Cite this as: BMJ 2010;341:c6413
  1. Steven Harkins, researcher, University of Strathclyde,
  2. Melissa Jones, managing editor, Powerbase
  1. melissa.jones{at}powerbase.info

Earlier this month, UK health secretary Andrew Lansley announced that the National Institute for Health and Clinical Excellence (NICE) would be stripped of its power to halt the purchase of drugs not considered cost effective for the NHS.1 He argued that the new system would be one where the “price of a drug will be determined by its assessed value”.2

The Stockholm Network, a pan-European think tank network, agreed with the proposed change to NICE’s remit. In a press release its chief executive, Helen Disney, argued that the move showed that, “even at a time of austerity, the British public does not want or accept rationed healthcare”.3

The network, which produces research for “market-oriented policy ideas in Europe”,4 has long had NICE within its sights. In …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe